Synergistic effects of β-amyloid and ceramide-induced insulin resistance on mitochondrial metabolism in neuronal cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 9, 2015, Pages 1810-1823

  Kwon, Bumsup ^a   Gamache, Timothy ^a   Lee, Han Kyu ^a   Querfurth, Henry W ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Ceramide; Insulin resistance; Mitochondrial dysfunction; amyloid

Indexed keywords

ACONITATE HYDRATASE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN[1-42]; CASPASE 9; CERAMIDE; CYCLIC AMP; CYCLOOXYGENASE 4; CYTOCHROME C OXIDASE; DYNAMIN RELATED PROTEIN 1; INSULIN; ISOCITRATE DEHYDROGENASE; MITOFUSIN 1; MITOGEN ACTIVATED PROTEIN KINASE; OXOGLUTARATE DEHYDROGENASE; PROSTAGLANDIN SYNTHASE; PROTEIN; PROTEIN KINASE B; PYRUVATE CARBOXYLASE; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; SUPEROXIDE; TIM13 PROTEIN; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VITAMIN;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL FRACTIONATION; CELL VIABILITY; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOSOLIC FRACTION; DOWN REGULATION; ENERGY YIELD; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN RESISTANCE; INSULIN RESPONSE; INTRACELLULAR SIGNALING; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MOUSE; NERVE CELL; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEOMICS; RAT; RESPIRATORY CHAIN; WESTERN BLOTTING;

EID: 84936150013     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.05.012     Document Type: Article

References (119)

1. Selkoe D.J. Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
2. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
3. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006, 5:64-74.
4. Lu F.P., Lin K.P., Kuo H.K. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009, 4:e4144.
5. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
6. de la Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep. 2009, 42:475-481.
7. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 2007, 4:147-152.
8. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
9. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr. Alzheimer Res. 2009, 6:213-223.
10. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J. Clin. Invest. 2012, 122:1339-1353.
11. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
12. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
13. Keller J.N., Schmitt F.A., Scheff S.W., Ding Q., Chen Q., Butterfield D.A., Markesbery W.R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64:1152-1156.
14. Mosconi L., Pupi A., De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1147:180-195.
15. Wirths O., Multhaup G., Czech C., Blanchard V., Moussaoui S., Tremp G., Pradier L., Beyreuther K., Bayer T.A. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001, 306:116-120.
16. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
17. Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006, 26:9057-9068.
18. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
19. Dragicevic N., Mamcarz M., Zhu Y., Buzzeo R., Tan J., Arendash G.W., Bradshaw P.C. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimers Dis. 2010, 20(Suppl. 2):S535-S550.
20. Keil U., Bonert A., Marques C.A., Scherping I., Weyermann J., Strosznajder J.B., Muller-Spahn F., Haass C., Czech C., Pradier L., Muller W.E., Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 2004, 279:50310-50320.
21. Casley C.S., Canevari L., Land J.M., Clark J.B., Sharpe M.A. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 2002, 80:91-100.
22. Rhein V., Baysang G., Rao S., Meier F., Bonert A., Muller-Spahn F., Eckert A. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell. Mol. Neurobiol. 2009, 29:1063-1071.
23. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
24. Chen J.X., Yan S.S. Role of mitochondrial amyloid-beta in Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S569-S578.
25. Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13145-13150.
26. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 1994, 63:2179-2184.
27. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21:455-462.
28. Cardoso S.M., Santana I., Swerdlow R.H., Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 2004, 89:1417-1426.
29. Crouch P.J., Blake R., Duce J.A., Ciccotosto G.D., Li Q.X., Barnham K.J., Curtain C.C., Cherny R.A., Cappai R., Dyrks T., Masters C.L., Trounce I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 2005, 25:672-679.
30. Bobba A., Amadoro G., Valenti D., Corsetti V., Lassandro R., Atlante A. Mitochondrial respiratory chain Complexes I and IV are impaired by beta-amyloid via direct interaction and through Complex I-dependent ROS production, respectively. Mitochondrion 2013, 13:298-311.
31. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell 2009, 20:1533-1544.
32. Shtifman A., Ward C.W., Laver D.R., Bannister M.L., Lopez J.R., Kitazawa M., LaFerla F.M., Ikemoto N., Querfurth H.W. Amyloid-beta protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol. Aging 2010, 31:2080-2090.
33. Veereshwarayya V., Kumar P., Rosen K.M., Mestril R., Querfurth H.W. Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of complex IV and limit apoptosis. J. Biol. Chem. 2006, 281:29468-29478.
34. Kim J.A., Wei Y., Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008, 102:401-414.
35. Bonnard C., Durand A., Peyrol S., Chanseaume E., Chauvin M.A., Morio B., Vidal H., Rieusset J. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J. Clin. Invest. 2008, 118:789-800.
36. Cheng Z., Tseng Y., White M.F. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 2010, 21:589-598.
37. Samad F., Badeanlou L., Shah C., Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv. Exp. Med. Biol. 2011, 721:67-86.
38. de la Monte S.M. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides ER stress, and insulin resistance reviewed. J. Alzheimers Dis. 2012, 30(Suppl. 2):S231-S249.
39. Hsieh C.T., Chuang J.H., Yang W.C., Yin Y., Lin Y. Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle. Cell. Signal. 2014, 26:1400-1408.
40. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 2006, 45:42-72.
41. Arboleda G., Huang T.J., Waters C., Verkhratsky A., Fernyhough P., Gibson R.M. Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur. J. Neurosci. 2007, 25:3030-3038.
42. de la Monte S.M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012, 72:49-66.
43. Haughey N.J., Bandaru V.V., Bae M., Mattson M.P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 2010, 1801:878-886.
44. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. Neruomol. Med. 2010, 12:331-340.
45. Magrane J., Rosen K.M., Smith R.C., Walsh K., Gouras G.K., Querfurth H.W. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J. Neurosci. 2005, 25:10960-10969.
46. Kwon B., Kumar P., Lee H.K., Zeng L., Walsh K., Fu Q., Barakat A., Querfurth H.W. Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis. Hum. Mol. Genet. 2014, 23:3681-3694.
47. Birch-Machin M.A., Turnbull D.M. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 2001, 65:97-117.
48. D.G.a.F.Nicholls S.J., et al. The chemiosmotic gradient 2002, Chapter 4., Academic Press, London. 3rd edition.
49. Lopez-Torres M., Gredilla R., Sanz A., Barja G. Influence of aging and long-term caloric restriction on oxygen radical generation and oxidative DNA damage in rat liver mitochondria. Free Radic. Biol. Med. 2002, 32:882-889.
50. Trounce I.A., Kim Y.L., Jun A.S., Wallace D.C. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996, 264:484-509.
51. Gnaiger E. Polarographic oxygen sensors, the oxygraph, and high-resolution respirometry to assess mitochondrial function. Drug-induced mitochondrial dysfunction 2008, 327-352.
52. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
53. Breen L., Cao L., Eom K., Srajer Gajdosik M., Camara L., Giacometti J., Dupuy D.E., Josic D. High-throughput fractionation of human plasma for fast enrichment of low- and high-abundance proteins. Blood Transfus 2012, 10(Suppl. 2):s89-s100.
54. Panagopoulos K., Cross-Knorr S., Dillard C., Pantazatos D., Del Tatto M., Mills D., Goldstein L., Renzulli J., Quesenberry P., Chatterjee D. Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol. Cancer 2013, 12:118.
55. Helou Y.A., Nguyen V., Beik S.P., Salomon A.R. ERK positive feedback regulates a widespread network of tyrosine phosphorylation sites across canonical T cell signaling and actin cytoskeletal proteins in Jurkat T cells. PLoS One 2013, 8. e69641.
56. Kwon B., Lee H.K., Querfurth H.W. Oleate prevents palmitate-induced mitochondrial dysfunction, insulin resistance and inflammatory signaling in neuronal cells. Biochim. Biophys. Acta 2014, 1843:1402-1413.
57. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
58. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
59. Viollet B., Horman S., Leclerc J., Lantier L., Foretz M., Billaud M., Giri S., Andreelli F. AMPK inhibition in health and disease. Crit. Rev. Biochem. Mol. Biol. 2010, 45:276-295.
60. Chaturvedi R.K., Flint Beal M. Mitochondrial diseases of the brain. Free Radic. Biol. Med. 2013, 63:1-29.
61. Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010, 20(Suppl. 2):S499-S512.
62. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
63. Wang X., Su B., Perry G., Smith M.A., Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic. Biol. Med. 2007, 43:1569-1573.
64. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
65. Moreira P.I., Santos M.S., Moreno A.M., Seica R., Oliveira C.R. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes 2003, 52:1449-1456.
66. Moreira P.I., Santos M.S., Sena C., Seica R., Oliveira C.R. Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol. Dis. 2005, 18:628-637.
67. Hong M., Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 1997, 272:19547-19553.
68. Altar C.A., Hunt R.A., Jurata L.W., Webster M.J., Derby E., Gallagher P., Lemire A., Brockman J., Laeng P. Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol. Psychiatry 2008, 64:1077-1087.
69. de la Monte S.M., Tong M., Nguyen V., Setshedi M., Longato L., Wands J.R. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J. Alzheimers Dis. 2010, 21:967-984.
70. Soeda Y., Tsuneki H., Muranaka H., Mori N., Hosoh S., Ichihara Y., Kagawa S., Wang X., Toyooka N., Takamura Y., Uwano T., Nishijo H., Wada T., Sasaoka T. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. Mol. Endocrinol. 2010, 24:1965-1977.
71. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
72. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
73. Alikhani N., Ankarcrona M., Glaser E. Mitochondria and Alzheimer's disease: amyloid-beta peptide uptake and degradation by the presequence protease, hPreP. J. Bioenerg. Biomembr. 2009, 41:447-451.
74. Falkevall A., Alikhani N., Bhushan S., Pavlov P.F., Busch K., Johnson K.A., Eneqvist T., Tjernberg L., Ankarcrona M., Glaser E. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome. PreP, J Biol Chem 2006, 281:29096-29104.
75. Alikhani N., Guo L., Yan S., Du H., Pinho C.M., Chen J.X., Glaser E., Yan S.S. Decreased proteolytic activity of the mitochondrial amyloid-beta degrading enzyme PreP peptidasome, in Alzheimer's disease brain mitochondria. J. Alzheimers Dis. 2011, 27:75-87.
76. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
77. Tong L., Balazs R., Thornton P.L., Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 2004, 24:6799-6809.
78. Jo J., Whitcomb D.J., Olsen K.M., Kerrigan T.L., Lo S.C., Bru-Mercier G., Dickinson B., Scullion S., Sheng M., Collingridge G., Cho K. Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat. Neurosci. 2011, 14:545-547.
79. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., Carmona-Cuenca I., Caballero C., Ruano D., Gutierrez A., Vitorica J. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J. Biol. Chem. 2011, 286:18414-18425.
80. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener. 2009, 4:14.
81. Wei W., Wang X., Kusiak J.W. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 2002, 277:17649-17656.
82. Martin D., Salinas M., Lopez-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J. Neurochem. 2001, 78:1000-1008.
83. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
84. Salkovic-Petrisic M., Tribl F., Schmidt M., Hoyer S., Riederer P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 2006, 96:1005-1015.
85. Abbott J.J., Howlett D.R., Francis P.T., Williams R.J. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol. Aging 2008, 29:992-1001.
86. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
87. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
88. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
89. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
90. Gonzalez E., McGraw T.E. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009, 8:2502-2508.
91. Zeyda M., Stulnig T.M. Obesity, inflammation, and insulin resistance-a mini-review. Gerontology 2009, 55:379-386.
92. Parra V., Eisner V., Chiong M., Criollo A., Moraga F., Garcia A., Hartel S., Jaimovich E., Zorzano A., Hidalgo C., Lavandero S. Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc. Res. 2008, 77:387-397.
93. Yu J., Novgorodov S.A., Chudakova D., Zhu H., Bielawska A., Bielawski J., Obeid L.M., Kindy M.S., Gudz T.I. JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J. Biol. Chem. 2007, 282:25940-25949.
94. Di Paola M., Cocco T., Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry 2000, 39:6660-6668.
95. Kogot-Levin A., Saada A. Ceramide and the mitochondrial respiratory chain. Biochimie 2014, 100:88-94.
96. Lim Y.A., Rhein V., Baysang G., Meier F., Poljak A., Raftery M.J., Guilhaus M., Ittner L.M., Eckert A., Gotz J. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 2010, 10:1621-1633.
97. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18670-18675.
98. Correia S.C., Santos R.X., Santos M.S., Casadesus G., Lamanna J.C., Perry G., Smith M.A., Moreira P.I. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr. Alzheimer Res. 2013, 10:406-419.
99. Hao L.Y., Giasson B.I., Bonini N.M. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9747-9752.
100. Chou J.L., Shenoy D.V., Thomas N., Choudhary P.K., Laferla F.M., Goodman S.R., Breen G.A. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 2011, 74:466-479.
101. Dabkowski E.R., Baseler W.A., Williamson C.L., Powell M., Razunguzwa T.T., Frisbee J.C., Hollander J.M. Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H529-H540.
102. Eccleston H.B., Andringa K.K., Betancourt A.M., King A.L., Mantena S.K., Swain T.M., Tinsley H.N., Nolte R.N., Nagy T.R., Abrams G.A., Bailey S.M. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid. Redox Signal. 2011, 15:447-459.
103. Ranieri M., Brajkovic S., Riboldi G., Ronchi D., Rizzo F., Bresolin N., Corti S., Comi G.P. Mitochondrial fusion proteins and human diseases. Neurol. Res. Int. 2013, 2013:293893.
104. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
105. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
106. Sugioka R., Shimizu S., Tsujimoto Y. Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis. J. Biol. Chem. 2004, 279:52726-52734.
107. Mecocci P., Polidori M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim. Biophys. Acta 2012, 1822:631-638.
108. Galasko D.R., Peskind E., Clark C.M., Quinn J.F., Ringman J.M., Jicha G.A., Cotman C., Cottrell B., Montine T.J., Thomas R.G., Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch. Neurol. 2012, 69:836-841.
109. Farina N., Isaac M.G., Clark A.R., Rusted J., Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 2012, 11:CD002854.
110. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
111. Reddy P.H., Tripathi R., Troung Q., Tirumala K., Reddy T.P., Anekonda V., Shirendeb U.P., Calkins M.J., Reddy A.P., Mao P., Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta 2012, 1822:639-649.
112. Pocernich C.B., Lange M.L., Sultana R., Butterfield D.A. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:452-469.
113. Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011, 51:1014-1026.
114. Lyn-Cook L.E., Lawton M., Tong M., Silbermann E., Longato L., Jiao P., Mark P., Wands J.R., Xu H., de la Monte S.M. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J. Alzheimers Dis. 2009, 16:715-729.
115. Ghafourifar P., Klein S.D., Schucht O., Schenk U., Pruschy M., Rocha S., Richter C. Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state. J. Biol. Chem. 1999, 274:6080-6084.
116. Gudz T.I., Tserng K.Y., Hoppel C.L. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J. Biol. Chem. 1997, 272:24154-24158.
117. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278:19777-19783.
118. Summers S.A., Garza L.A., Zhou H., Birnbaum M.J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 1998, 18:5457-5464.
119. Lee J.K., Jin H.K., Park M.H., Kim B.R., Lee P.H., Nakauchi H., Carter J.E., He X., Schuchman E.H., Bae J.S. Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. J. Exp. Med. 2014, 211:1551-1570.